These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8405332)

  • 1. Prolonged hematological remission by mitoxantrone and interferon--alpha-2b in a child with resistant Philadelphia chromosome-positive chronic myelogenous leukemia.
    Duru F; Tuncer M; Hiçsönmez G
    Eur J Haematol; 1993 Sep; 51(3):173-4. PubMed ID: 8405332
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete cytogenetic and molecular remission in a case of lymphoid blast crisis in chronic myeloid leukemia with intensive chemotherapy and interferon alpha.
    Fabbiano F; Santoro A; Di Trapani F; Marino MA; Pampinella M; Caronia F
    Eur J Haematol; 1993 Aug; 51(2):122-3. PubMed ID: 8370420
    [No Abstract]   [Full Text] [Related]  

  • 3. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
    Opalka B; Wandl UB; Becher R; Kloke O; Nagel-Hiemke M; Moritz T; Beer U; Seeber S; Niederle N
    Blood; 1991 Nov; 78(9):2188-93. PubMed ID: 1932740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial cytoreduction by mitoxantrone and cytarabine has no impact on the outcome of interferon-alfa-2b therapy in chronic myelogenous leukemia.
    Nielsen H; Nielsen JL; Karle H
    Eur J Haematol; 1992 Aug; 49(2):67-70. PubMed ID: 1397243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrasomy of Philadelphia chromosome in myeloblastic crisis of chronic myelogenous leukemia.
    Oikawa H; Utsugisawa T; Murai K; Narigasawa Y; Miyairi Y; Shimosegawa K; Suzuki T; Kuriya S
    Int J Hematol; 1995 Jun; 61(4):229-30. PubMed ID: 8547613
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
    Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
    Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
    Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
    Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.
    Kanda Y; Chiba S; Honda H; Hirai H; Yazaki Y
    Leuk Lymphoma; 1999 Mar; 33(1-2):193-7. PubMed ID: 10194138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
    Kantarjian HM; Talpaz M
    Leuk Lymphoma; 1993; 11 Suppl 1():169-74. PubMed ID: 8251891
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
    Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
    Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic myelogenous leukemia with interferons: hematologic, cellular, and genetic investigations.
    Opalka B; Kloke O; Wandl U; Becher R; Niederle N
    Haematol Blood Transfus; 1989; 32():134-8. PubMed ID: 2516494
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.
    Kloke O; Wandl U; Opalka B; Moritz T; Nagel-Hiemke M; Franz T; Becher R; Hirche H; Seeber S; Niederle N
    Eur J Haematol; 1992 Feb; 48(2):93-8. PubMed ID: 1547881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and hematological remission after a single dose of mitoxantrone in a child with Philadelphia chromosome-positive chronic myeloid leukemia.
    Oner AF; Hiçsönmez G; Olcay L
    Pediatr Hematol Oncol; 1997; 14(5):483-6. PubMed ID: 9267882
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cytogenetic remission 10 years after the start of monotherapy with interferon alpha-2b in elderly chronic myelogenous leukemia].
    Umeda M; Katoh M; Arai C; Iijima K
    Nihon Ronen Igakkai Zasshi; 2003 Sep; 40(5):520-5. PubMed ID: 14579725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early lymphoid blastic crisis following major karyotypic conversion in a chronic myeloid leukemia patient treated with interferon-alpha.
    Ambrosetti A; Krampera M; Veneri D; Meneghini V; Aprili F; Martinelli G; Pizzolo G; Perona G
    Int J Clin Lab Res; 1994; 24(1):58-9. PubMed ID: 8180425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
    Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
    Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon therapy for chronic myelogenous leukemia].
    Shibata A; Hashimoto S
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):200-6. PubMed ID: 8434957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving approaches with interferon alfa in chronic myelogenous leukemia.
    Morra E; Alimena G; Lazzarino M; Liberati AM; Montefusco E; Bernasconi P; Mancini M; Donti E; Merante S; Caricchi P
    Semin Hematol; 1993 Jul; 30(3 Suppl 3):26-7. PubMed ID: 8235701
    [No Abstract]   [Full Text] [Related]  

  • 20. Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.
    Eberlé F; Toiron Y; Camerlo J; Lafage M; Sainty D; Arnoulet C; Raineri V; Gabert J; Maraninchi D; Mannoni P
    Leuk Lymphoma; 1995 Jun; 18(1-2):153-7. PubMed ID: 8580818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.